secwatch.observer — SEC 8-K summary
======================================

Issuer:     ORAGENICS INC (OGEN)
CIK:        0001174940
Form:       8-K
Filed at:   2025-03-27T23:59:59+00:00
Accession:  0001641172-25-000855
Event type: other_material
Sentiment:  positive
Materiality: 0.50
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Oragenics Q1 update: $5M raised, ONP-002 Phase IIa trial advances
-----------------------------------------------------------------

- Raised ~$2.6M via ATM equity and ~$2.25M via non-dilutive debt; submitted DoD grant for concussion program.
- Submitted Investigator's Brochure for Phase IIa trial in Australia; trial listed on ClinicalTrials.gov; awaiting HREC approval.
- Partnered with BRAINBox Solutions to combine intranasal ONP-002 with diagnostic biomarkers for personalized concussion care.
- Upcoming milestones: HREC approval and first patient enrollment in Q2 2025; Phase IIa enrollment completion by Q4 2025.
- Simplified capital structure by converting all preferred shares to common; annual meeting set for May 2, 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1174940/000164117225000855/0001641172-25-000855-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1174940/000164117225000855/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001641172-25-000855

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer